Apr 27, 2020 12:01am EDT Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Apr 20, 2020 4:35pm EDT Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
Apr 13, 2020 5:00pm EDT Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
Mar 16, 2020 7:00am EDT Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments
Mar 12, 2020 7:00am EDT Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
Mar 04, 2020 7:00am EST Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London
Feb 27, 2020 7:00am EST Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference
Feb 05, 2020 7:30am EST Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development